Dual antagonist of TP and EP4 receptors
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

AH 23848 (calcium salt)

Item No. 19023

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(4Z)-rel-7-[(1R,2R,5S)-5-([1,1'-biphenyl]-4-ylmethoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid, hemicalcium salt
CAS Number
81496-19-7
Molecular Formula
C29H34NO5 • 1/2Ca
Formula Weight
496.6
Purity
≥90%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: >5mg/ml
λmax
254 nm
SMILES
O=C1C[C@H](OCC2=CC=C(C3=CC=CC=C3)C=C2)[C@H](CC/C=C\CCC([O-])=O)[C@H]1N4CCOCC4.O=C5C[C@H](OCC6=CC=C(C7=CC=CC=C7)C=C6)[C@H](CC/C=C\CCC([O-])=O)[C@H]5N8CCOCC8.[Ca+2]
InChi Code
InChI=1S/2C29H35NO5.Ca/c2*31-26-20-27(35-21-22-12-14-24(15-13-22)23-8-4-3-5-9-23)25(10-6-1-2-7-11-28(32)33)29(26)30-16-18-34-19-17-30;/h2*1-5,8-9,12-15,25,27,29H,6-7,10-11,16-21H2,(H,32,33);/q;;+2/p-2/b2*2-1-;/t2*25-,27-,29+;/m00./s1
InChi Key
JDEBIDDIERGZQY-KFZBTSSDSA-L
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $91

    Add

    5 mg

    $293

    Add

    10 mg

    $539

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Thromboxane (TXA2) activates the T prostanoid (TP) receptor. Prostaglandin E2 (PGE2) activates four E prostanoid (EP) receptors, EP1-4. AH 23848 is a dual antagonist of TP and EP4 receptors.1,2 It originally was found to inhibit TXA2-induced platelet aggregation (IC50 = 0.26 μM) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.1,3 AH 23848 was subsequently demonstrated to impair PGE2-mediated relaxation of piglet saphenous vein by antagonizing the PGE2 receptor EP4.2 By inhibiting EP4, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts, as well as reduces metastasis in a mouse model of metastatic breast cancer.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Brittain, R.T., Boutal, L., Carter, M.C., et al. AH23848: A thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation 72, 1208-1218 (1985).

    2. Coleman, R.A., Grix, S.P., Head, S.A., et al. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47, 151-168 (1994).

    3. Coleman, R.A., and Sheldrick, R.L.G. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 96(3), 688-692 (1989).

    4. Sanchez, T., and Moreno, J.J. Role of EP1 and EP4 PGE2 subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. Am. J. Physiol. Cell Physiol. 282(2), C280-C288 (2002).

    5. Ma, X., Kundu, N., Rifat, S., et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66(6), 2923-2927 (2006).